Eduardo Rodríguez-Arbolí

18PUBLICATIONS
106CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursOtorhinolaryngologyMedical infection agents (incl. prions)Cardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 30, 2026
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

|May 07, 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.

|Apr 22, 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

|Apr 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Juan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil

|Feb 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard

|Oct 13, 2025
Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?

E Rodríguez-Arbolí, R P Gale

Pageof 3

Frequent Collaborators

9 joint publications

Pau Montesinos

5 joint publications

Rebeca Rodríguez-Veiga

5 joint publications

Juan Miguel Bergua-Burgues

5 joint publications

David Martínez-Cuadrón